Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network

Raiker R., Pakhchanian H., Kavadichanda C., Gupta L., Kardes S., Ahmed S.

CLINICAL RHEUMATOLOGY, cilt.41, sa.3, ss.721-730, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s10067-021-05979-y
  • Dergi Adı: CLINICAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.721-730
  • Anahtar Kelimeler: Ankylosing spondylitis, COVID-19, Multicentric cohort, Outcomes, Spondyloarthritis, TUMOR-NECROSIS-FACTOR, TNF
  • İstanbul Üniversitesi Adresli: Evet

Özet

Introduction The outcomes of COVID-19 in patients with axial spondyloarthritis (ax-SpA) have not been explored in detail. Tumour necrosis factor inhibitors (TNFi) are commonly used for ax-SpA patients, and how they influence outcomes may have implications on COVID-19 management.